Results 11 to 20 of about 29,549 (204)

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

npj Precision Oncology
ROS1 tyrosine kinase inhibitors (TKIs) are highly effective in ROS1-positive non-small cell lung cancer, but resistance remains a challenge. We investigated the activity of various TKIs against wildtype and mutant ROS1, focusing on the emerging L2086F ...
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z. Beach, Guilherme Harada, Alexander Drilon, Monika A. Davare   +9 more
doaj   +5 more sources

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas [PDF]

American Journal of Surgical Pathology, 2013
ROS1 gene rearrangements are reported in 1% to 2% of lung adenocarcinomas (ACAs) and are associated with response to the multitargeted tyrosine kinase inhibitor crizotinib. ROS1 rearrangements can be detected using fluorescence in situ hybridization (FISH); however, immunohistochemistry (IHC) for ROS1 protein is a promising alternate screening modality.
Sholl, Lynette, Sun, Heather, Butaney, Mohit, Zhang, Chengsheng, Lee, Charles, Janne, Pasi, Rodig, Scott   +6 more
openaire   +3 more sources

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS1 Rearrangement [PDF]

Cancer Med
Survival outcomes in gradual/local progression group were superior to dramatic progression group; survival period of dramatic progression group who received chemotherapy was longer than that of other therapies. ROS1 kinase domain mutations were detected predominantly in dramatic progression group, whereas activation of bypass and downstream pathways ...
Tan Q, Chen Y, Gao Y, Liu K, Mao Z, Zheng M, Su J, Yang J, Gao Q, Chen H, Yang J.   +10 more
europepmc   +2 more sources

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

Frontiers in Immunology, 2020
The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable.
Liangliang Cai, Liangliang Cai, Liangliang Cai, Jianchun Duan, Li Qian, Li Qian, Zhijie Wang, Shuhang Wang, Sini Li, Chao Wang, Jie Zhao, Xue Zhang, Hua Bai, Jie Wang   +13 more
doaj   +1 more source

SUVH1, a Su(var)3-9 family member, promotes the expression of genes targeted by DNA methylation. [PDF]

, 2015
Transposable elements are found throughout the genomes of all organisms. Repressive marks such as DNA methylation and histone H3 lysine 9 (H3K9) methylation silence these elements and maintain genome integrity.
Chen, Xuemei, Gao, Lei, Kim, Yun Ju, Li, Shaofang, Li, Shengben, Liu, Lin, Zhao, Yuanyuan   +6 more
core   +2 more sources

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. [PDF]

, 2015
BackgroundPemetrexed is approved in the treatment of advanced stage nonsquamous non-small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify which clinicopathologic characteristics are associated with long-term ...
Liang, Ying, Neal, Joel W, Wakelee, Heather A   +2 more
core   +1 more source

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors [PDF]

Modern Pathology, 2015
Inflammatory myofibroblastic tumor is a distinctive, rarely metastasizing mesenchymal neoplasm composed of fascicles of spindle cells with a prominent inflammatory infiltrate. Roughly 50% of inflammatory myofibroblastic tumors harbor ALK receptor tyrosine kinase gene rearrangements. Such tumors are usually positive for ALK by immunohistochemistry.
Jason L, Hornick, Lynette M, Sholl, Paola, Dal Cin, Merrida A, Childress, Christine M, Lovly   +4 more
openaire   +2 more sources

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. [PDF]

PLoS ONE, 2014
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotinib. We investigated the usefulness of ROS1 immunohistochemistry (IHC) for the detection of patients who harbor ROS1 rearrangements in two separate cohorts.
Yoon Jin Cha, Jae Seok Lee, Hye Ryun Kim, Sun Min Lim, Byoung Chul Cho, Chang Young Lee, Hyo Sup Shim   +6 more
doaj   +1 more source

Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins [PDF]

Journal of Thoracic Oncology, 2018
The identification of key oncogenic driver alterations in NSCLC has led to the development of tailored treatments. ROS1 rearrangements occur in 1% to 2% of NSCLC.1 Dysregulation of MNNG HOS Transforming gene (MET) signaling through MET exon 14 skipping mutations or MET amplification has been reported in 3% to 4% and 2% to 5% of adenocarcinomas ...
Rihawi K, Cinausero M, Fiorentino M, SALVAGNI, SANDRO, Brocchi S, Ardizzoni A   +5 more
openaire   +2 more sources

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study

Molecular Oncology, 2023
ROS proto‐oncogene 1, receptor tyrosine kinase (ROS1) rearrangements are a crucial therapeutic target in non‐small cell lung cancer (NSCLC). However, there is limited comprehensive analysis of the molecular patterns of ROS1 fusions.
Shengyu Zhou, Fayan Zhang, Mengxiang Xu, Lei Zhang, Zhengchuang Liu, Qiong Yang, Chunyang Wang, Baoming Wang, Tonghui Ma, Jiao Feng   +9 more
doaj   +1 more source